Add to ORKGLung cancer is one of the most common causes in cancer-associated deaths, in which non-small cell lung cancer (NSCLC) accounts for 85 % and most patients are in middle and advanced stage when being diagnosed (Li e
For advanced non-squamous non-small cell lung cancer (NSCLC), although platinum/pemetrexed is known ...
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. About 50...
Abstract Locally advanced non-small cell lung cancer (NSCLC) continues to be a challenging disease t...
Lung cancer incidence continues to rise and is the number one cause of cancer death in both men and ...
To compare the efficacy and toxicities of pemetrexed plus platinum with other platinum regimens in p...
Background and objective Pemetrexed in combination with platinum or a single-agent has been approved...
Non-small cell lung cancer (NSCLC) is still the leading cause of cancer-related death, and the treat...
Background and objective Since the poor outcome for advanced lung cancer with first-line chemotherap...
The efficacy and safety of chemotherapy as third- or higher-line therapy for advanced non-small cell...
Serena Ricciardi1, Silverio Tomao2, Filippo de Marinis11Thoracic-Oncology Unit 1st, Lung Diseases De...
Objective: Lung cancer Pemetrexed is novel multitargeted antifolate which inhibits three key enzymes...
Platinum-based chemotherapy doublets have been the standard approach to first-line therapy for more ...
International audienceStandard first-line therapy for metastatic, squamous non-small-cell lung cance...
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death. The American Societ...
Abstract Background The objective of this study was to evaluate the efficacy and safety of pemetrexe...
For advanced non-squamous non-small cell lung cancer (NSCLC), although platinum/pemetrexed is known ...
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. About 50...
Abstract Locally advanced non-small cell lung cancer (NSCLC) continues to be a challenging disease t...
Lung cancer incidence continues to rise and is the number one cause of cancer death in both men and ...
To compare the efficacy and toxicities of pemetrexed plus platinum with other platinum regimens in p...
Background and objective Pemetrexed in combination with platinum or a single-agent has been approved...
Non-small cell lung cancer (NSCLC) is still the leading cause of cancer-related death, and the treat...
Background and objective Since the poor outcome for advanced lung cancer with first-line chemotherap...
The efficacy and safety of chemotherapy as third- or higher-line therapy for advanced non-small cell...
Serena Ricciardi1, Silverio Tomao2, Filippo de Marinis11Thoracic-Oncology Unit 1st, Lung Diseases De...
Objective: Lung cancer Pemetrexed is novel multitargeted antifolate which inhibits three key enzymes...
Platinum-based chemotherapy doublets have been the standard approach to first-line therapy for more ...
International audienceStandard first-line therapy for metastatic, squamous non-small-cell lung cance...
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death. The American Societ...
Abstract Background The objective of this study was to evaluate the efficacy and safety of pemetrexe...
For advanced non-squamous non-small cell lung cancer (NSCLC), although platinum/pemetrexed is known ...
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. About 50...
Abstract Locally advanced non-small cell lung cancer (NSCLC) continues to be a challenging disease t...